The findings offer promising support for progressing ADPO-002NP treatment to first-in-human Phase I clinical trials. Adipo Therapeutics LLC, a late-stage preclinical biopharmaceutical company focused on developing treatments for obesity and related metabolic disorders, recently presented findings f
